Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax infections, and smoking cessation.

Type
Public
HQ
Hayward, US
Founded
1991
Size (employees)
23 (est)+44%
Aradigm was founded in 1991 and is headquartered in Hayward, US
Report incorrect company information

Key People/Management at Aradigm

Igor Gonda

Igor Gonda

President & Chief Executive Officer
Nancy Pecota

Nancy Pecota

CFO
Juergen Froehlich

Juergen Froehlich

Chief Medical Officer
David Cipolla

David Cipolla

Vice President Preclinical R&D
Show more

Aradigm Office Locations

Aradigm has an office in Hayward
Hayward, US (HQ)
3929 Point Eden Way
Show all (1)
Report incorrect company information

Aradigm Financials and Metrics

Aradigm Revenue

Aradigm's revenue was reported to be $14.47 m in FY, 2017
USD

Revenue (Q1, 2018)

1.5 m

EBIT (Q1, 2018)

(3.8 m)

Market capitalization (11-Jul-2018)

21.8 m

Closing share price (11-Jul-2018)

1.4

Cash (31-Mar-2018)

1.4 m
Aradigm's current market capitalization is $21.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

9.7 m33.6 m23.4 m195 k14.5 m

Revenue growth, %

245%(30%)(99%)

General and administrative expense

5.8 m7.6 m

R&D expense

24.4 m13.8 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

4.6 m6.6 m12.2 m6.6 m8.8 m10 m4.7 m6 k14 k50 k1.7 m7.7 m2.7 m1.5 m

General and administrative expense

1.5 m1.7 m1.9 m1.4 m1.5 m1.3 m1.3 m1.6 m1.4 m1.5 m1.7 m1.9 m1.7 m

R&D expense

1.6 m5.8 m11.7 m6 m8.4 m9.8 m8.9 m6.5 m6.2 m5.8 m2.8 m3.8 m3.6 m

Operating expense total

19 m7.5 m13.6 m7.5 m9.9 m11.1 m10.2 m8.1 m7.6 m7.3 m4.5 m5.7 m5.7 m5.3 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

48.1 m48 m31.5 m22.6 m7.1 m

Accounts Receivable

499.1 m200 k

Inventories

Current Assets

49.7 m50.5 m35.2 m24.8 m7.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

38.7 m41.7 m50.3 m48.5 m48.6 m49 m40 m22.4 m31.2 m28.5 m17.2 m12 m12.6 m1.4 m

Accounts Receivable

183 k

Current Assets

53.3 m45.9 m52.6 m49.8 m50.8 m50.9 m41.6 m26.5 m35.7 m32 m19.7 m13 m13.6 m2.3 m

PP&E

461 k493 k539 k582 k416 k353 k325 k310 k282 k278 k225 k227 k256 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(21.6 m)4.7 m(17.2 m)(32.9 m)(10.7 m)

Depreciation and Amortization

370 k310 k203 k121 k118 k

Inventories

Accounts Payable

289 k2.1 m(917 k)(1.1 m)193 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018

Net Income

(14.9 m)7.8 m(1.4 m)(914 k)(1.1 m)(5.5 m)(4.8 m)

Depreciation and Amortization

34 k

Accounts Payable

4 m1.4 m2 m3 m1.9 m2.5 m1.2 m956 k532 k980 k(69 k)

Cash From Operating Activities

(5.8 m)
Show all financial metrics

Aradigm Operating Metrics

FY, 2014FY, 2015FY, 2016

Patents Issued

82 82 80

Patents Pending

35 27 49
Show all operating metrics
Report incorrect company information

Aradigm Online and Social Media Presence

Embed Graph
Report incorrect company information

Aradigm News and Updates

Bronchiectasis Treatment Market: Industry Drivers, Opportunities, Trends and Forecasts 2017 - 2025

The global bronchiectasis treatment market is expected to register a significant CAGR over a forecast period. Posted via Industry Today. Follow us on Twitter @IndustryToday

Bronchiectasis Treatment Market Is Expected To Generate Huge Profits by 2025

Bronchiectasis refers to a condition characterized by damaged airways (tubes) and affect their ability to clear out the mucus. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information

Aradigm Company Life and Culture

Report incorrect company information